Member Info for Laura2022

Yes sharebel

Namely

1) can't trust a word you say AB

2) you've never delivered anything apart from dilution

interests with the potential - subject to all the usual caveats 

"Expects"....... and each one already 6mth+ over due

The following is an update of key points only in relation to the Company's assets and current developments. For a more comprehensive summary of the Company's assets, the Company's website may be referred to.

Highlights:

o  Red Rock expects the most important near-term developments to be:

o  Gold production in Burkina Faso

o  Release of arbitration result in the Democratic Republic of Congo ("DRC")

o  Further updates on New Ballarat Gold Corporation

Comment: Red Rock CEO Andrew Bell states: "Our confidenc

£13.2m loan secured to fund future capital investment

 

Customer highlights

· Increased order book by £100m (lifetime value) to £390m at the end of the year

· Further demonstrated the ability to win "carry over" business with existing customer OEM 10

· 5 contracts in multi-year revenue generation phase

· Customers have been critical but supportive in response to our production difficulties

Laura2022

Posted in: SCE

Posts: 4,584

Price: 0.375

No Opinion

From another website6 Oct 2024 09:11

Apparently this was posted last night in telegram

Rumoured possible Cheap OEM or strategic take over here.. what price will it be?.. probs around 1p imo, thats after having taken a big stake last week. Around 40% stock sold… decent 15m block buy late Friday too at 0.53p someone wanting the stock!.… expecting fire works here soon. If the OEM’s have £400m of orders awaiting delivery then makes total sense to take the lot ..cheap.. they’ll save a packet on costs and can then ride out the development phases taking all the spoils when completed. Not rocket science here, especially with £100m spent to date

Inaphaea and BioRep will be entitled to a percentage of service or sales royalties on relevant contracts introduced by the respective party. Both companies have also agreed to co-market their respective services.

Andrew Carnegie, Head of Strategic Commercial Development at Inaphaea, commented "This deal with BioRep expands our reach into Europe whilst providing backup storage and disaster management solutions."

Mark Eccleston, CEO of ValiRx, commented "BioRep is an excellent partner as we look to offer our PDC product line into European markets. Their expertise in sample management, characterisation capabilities and access to a broad client base as well as logistics are a great fit for Inaphaea."

£18k and £60knbougut at 0.53p Friday

Filtered

Good to see you're happy with human misery

It's you're not your

Please brush up GG

Ps

It's vain not vein

Xx

GG

Your family are proud of you

Precision medicine mentioned agian

14:45

Just for interest:

Guardian article yesterday on lung cancer trial having great results stopping advancement of cancer by 40%. Further, it refers to , quote “….part of treatment called “precision“ medicine. Advances in precision medicine have led to new treatments tailored - etc…”.

I personally don't see a bid/offer

Instead some positive news regarding loans/ customer invoicing

Yes...the large late trades probably went un noticed but now the weekend word has spread and we should see fireworks Monday

Very good point Jordie

Usually a buy like that would be reported 1hr or even 1day late

The fact it was live and so much above the ask suggests someone wanted in quickly

£13.2m loan secured to fund future capital investment

 

Customer highlights

· Increased order book by £100m (lifetime value) to £390m at the end of the year

· Further demonstrated the ability to win "carry over" business with existing customer OEM 10

· 5 contracts in multi-year revenue generation phase

· Customers have been critical but supportive in response to our production difficulties

Apparently this was posted last night in telegram

Rumoured possible Cheap OEM or strategic take over here.. what price will it be?.. probs around 1p imo, thats after having taken a big stake last week. Around 40% stock sold… decent 15m block buy late Friday too at 0.53p someone wanting the stock!.… expecting fire works here soon. If the OEM’s have £400m of orders awaiting delivery then makes total sense to take the lot ..cheap.. they’ll save a packet on costs and can then ride out the development phases taking all the spoils when completed. Not rocket science here, especially with £100m spent to date.

But unfortunately at the moment the majority of people with cancer see no benefit from immunotherapy.

Many suffer a relapse or experience significant side effects, which can include painful inflammation in the bowel, skin or the lungs.

So now a new multimillion-pound research programme aims to discover why at least half of all patients fail to respond to immunotherapy or suffer from those debilitating side effects

Thanks Ralph

With the beyondblood/PYC test developing well and the OBD cancer prostate test clearly not selling (see their last 2yrs financial results) , is there now a huge gap for the test developed by PYC/BB